Nuveen Asset Management, LLC Jounce Therapeutics, Inc. Transaction History

Nuveen Asset Management, LLC

$345 Billion
Q3 2024

16 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 15, 2023	SELL	$0.9 - $1.85 $9,517 - $19,563	-10,575 Reduced 8.05%	120,810 $223,000
Q4 2022 Feb 14, 2023	BUY	$0.64 - $1.99 $9,875 - $30,707	15,431 Added 13.31%	131,385 $146,000
Q3 2022 Nov 14, 2022	SELL	$2.73 - $4.92 $113,909 - $205,287	-41,725 Reduced 26.46%	115,954 $272,000
Q2 2022 Aug 15, 2022	SELL	$2.8 - $7.67 $4,454 - $12,202	-1,591 Reduced 1.0%	157,679 $478,000
Q1 2022 May 16, 2022	SELL	$6.01 - $8.54 $22,639 - $32,170	-3,767 Reduced 2.31%	159,270 $1.03 Million
Q4 2021 Feb 14, 2022	SELL	$7.11 - $9.64 $28,603 - $38,781	-4,023 Reduced 2.41%	163,037 $1.14 Million
Q3 2021 Nov 12, 2021	BUY	$5.04 - $8.73 $56,946 - $98,640	11,299 Added 7.25%	167,060 $1.3 Million
Q2 2021 Aug 16, 2021	BUY	$6.58 - $10.66 $196,334 - $318,073	29,838 Added 23.7%	155,761 $1.06 Million
Q1 2021 May 17, 2021	BUY	$6.73 - $13.87 $8,681 - $17,892	1,290 Added 1.04%	125,923 $1.29 Million
Q4 2020 Feb 16, 2021	BUY	$6.37 - $10.33 $347,789 - $563,997	54,598 Added 77.96%	124,633 $872,000
Q3 2020 Nov 16, 2020	BUY	$4.58 - $10.95 $164 - $394	36 Added 0.05%	70,035 $571,000
Q2 2020 Aug 14, 2020	BUY	$4.17 - $7.58 $8,185 - $14,879	1,963 Added 2.89%	69,999 $483,000
Q1 2020 May 14, 2020	BUY	$2.91 - $8.7 $28,986 - $86,660	9,961 Added 17.15%	68,036 $323,000
Q4 2019 Feb 14, 2020	SELL	$2.81 - $9.21 $69,584 - $228,067	-24,763 Reduced 29.89%	58,075 $507,000
Q3 2019 Nov 14, 2019	SELL	$3.33 - $4.93 $190,739 - $282,385	-57,279 Reduced 40.88%	82,838 $276,000
Q2 2019 Aug 15, 2019	BUY	$4.3 - $6.73 $602,503 - $942,987	140,117 New	140,117 $693,000

Others Institutions Holding JNCE

# of Institutions

Shares Held

720K

Call Options Held

Put Options Held

View Full List

About Jounce Therapeutics, Inc.

Ticker JNCE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 51,694,200
Description
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. The company develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid ...

More about JNCE

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nuveen Asset Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nuveen Asset Management, LLC with notifications on news.

Account